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Recent observations in cultured human fibroblasts suggest that the accumulation of point mutations in the noncoding
control region of mtDNA may be important in human aging. We studied the mtDNA control region in brain tissue
from 31 normal elderly individuals, from 35 individuals who had Alzheimer disease, and from 47 individuals who
had dementia with Lewy bodies. We found no evidence that these somatic mtDNA point mutations accumulate
either in the brains of normal elderly individuals or in the brains of individuals with neurodegenerative disease.
It has been suggested that the accumulation of somat-
ic mtDNA mutations may contribute to the aging pro-
cess. Various mtDNA deletions accumulate in postmi-
totic tissues, including skeletal muscle (Cortopassi and
Arnheim 1990) and brain (Corral-Debrinski et al. 1992).
Although these deletions are present at low levels (!2%)
in whole tissue, mutations may clonally expand, reach-
ing high levels within individual cells (Brierley et al.
1998). When the percentage of these mutations exceeds
a critical threshold within a single cell, this may cause
a defect of mitochondrial oxidative metabolism andmay
ultimately lead to cell death.
Point mutations in the noncoding mtDNA control re-
gion have also been detected in human fibroblasts from
normal, elderly individuals (Michikawa et al. 1999).
These mutations were not detected in fibroblasts from
young individuals, and longitudinal studies showed that
these mutations appeared with advancing age. One par-
ticular mutation (T414G) reached high levels (as high
as 50%) and was detected in fibroblasts from more than
half the older subjects. Although the mutations in that
study were not associated with any obvious phenotypic
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effects, they occurred in the region that is crucial for
mtDNA replication and transcription, thereby raising
the possibility that they may have a detrimental effect
on mitochondrial function within single cells.
The experiments of Michikawa et al. (1999) were per-
formed on cultured fibroblasts from skin, a tissue in
which cell proliferation continues throughout life. We
have a long-standing interest in the role of mtDNA mu-
tations in aging, particularly in postmitotic cells. Fur-
thermore, like others (e.g., Pennisi 1999), we were con-
cerned about the significance of these findings for aging
in the human brain and for neurodegenerative disease.
We therefore studied the mtDNA control region in DNA
extracted from frozen brain tissue of both normal elder-
ly individuals and individuals with neurodegenerative
disease.
Postmortem control brain tissue was from individu-
als ( ; mean age [SD] 71.7 [10.21] years) whonp 31
showed no clinical evidence of dementia before death
and who had only age-associated pathological abnor-
malities without Lewy bodies. Of the control brain tissue
samples, 20 were from individuals who died at 70
years of age. Individuals with neurodegenerative disease
were classified, on the basis of clinical examination be-
fore death, as having either Alzheimer disease (AD)
( ; mean age [SD] 77.9 [9.55] years) or dementianp 35
with Lewy bodies (DLB) ( ; mean age [SD] 79.1np 47
[5.51] years), and the diagnosis was confirmed at au-
topsy, with the use of established neuropathological cri-
teria (Perry et al. 1996). Individuals who had extensive
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Figure 1 The mtDNA control region, showing the position of the sequence changes seen in brain tissue isolated from elderly normal
individuals ( ) and from individuals with either AD ( ) or DLB ( ), at nt 100–576 (numbered according to the revisednp 31 np 35 np 47
Cambridge Reference Sequence [Anderson et al. 1981; Andrews et al. 1999]). CSB p conserved sequence blocks; d p deletion; ip insertion;
LSP p light-strand promoter; mtTFA p binding site for mitochondrial transcription factor A; OHp origin of heavy-strand replication; tRNA
Phe p tRNA phenylalanine gene; tRNA Pro p tRNA proline gene.
mixed pathology, including those with multiple cerebral
infarcts, were excluded.
DNA was extracted from 300 mg of frozen brain tis-
sue. The most prominent age-associated control-region
mutations reported by Michikawa et al. (1999) mapped
to the region between nucleotides (nt) 333 and 785 of
the control region (A386G, 383i, and T414G).We there-
fore sequenced nt 333–785 of the control region in the
brain DNA samples, with the use of M13-tagged prim-
ers, Big-Dye terminator cycle sequencing, and an ABI
377 automated DNA sequencer (PE Biosystems), as de-
scribed elsewhere (Andrews et al. 1999). Serial-dilution
experiments indicate that low levels (20%) of mtDNA
heteroplasmy cannot be reliably detected by our auto-
mated sequencing protocol. This limitation raised the
possibility that we did not detect mutations that reached
high percentage levels within a small number of neurons.
To determine whether low-frequencymutationswere un-
detected in our nucleotide-sequencing approach, we an-
alyzed the T414G transversion in the brain tissues of 37
normal elderly persons and the brain tissues of 35 in-
dividuals who had AD, by use of fluorescent primer-
extension reaction (fPEA), according to a modification
of the protocol of Fahy et al. (1997), with the use of a
FAM-labeled primer ttg ggt ggt gac tgt taa aag tgc (de-
tails available on request from P.F.C.). This technique
allows the detection of low levels (!1%) of mtDNA het-
eroplasmy when the reaction products are electropho-
resed through a 12% denaturing polyacrylamide gel on
an ABI 373 genetic analyzer (PE Biosystems).
mtDNA sequencing identified numerous base substi-
tutions within the control region, with reference to the
revised Cambridge mtDNA sequence (Anderson et al.
1981; Andrews et al. 1999) (fig. 1). All the sequence
changes appeared to be homoplasmic on the sequenc-
ing chromatogram. With the exception of one change
(T466C), all these changes have been detected before in
blood or bone samples from healthy young individuals
(N.H. and T.J.P., unpublished observations; HVR-Base
of the Max Planck Institute for Evolutionary Genetics;
MITOMAP: a Human Mitochondrial Genome Data-
base; also see Mitosearch mtDNA Analysis Software,
version 2.0 [available from the Federal Bureau of In-
vestigation]). The T466C polymorphism is 3′ to the light-
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strand promoter region and its associated mitochondri-
al transcription factor A binding site (fig. 1). It was seen
in the brain tissue of one patient with AD and also ap-
peared to be homoplasmic on the sequencing chromato-
gram. Private mtDNA polymorphisms are not uncom-
mon (e.g., see Anderson et al. 1981; Andrews et al.
1999), and it is likely that all the sequence changes that
we detected in the mtDNA control region of the brain
DNA are maternally inherited mtDNA polymorphisms.
Sequencing did not detect the A386G, 383i, or T414G
polymorphisms in any of the 113 samples of brain DNA.
fPEA did not detect the T414G mutation in the brain
tissue of either control subjects or individuals with AD.
We did not detect any of the mtDNA control region
mutations reported by Michikawa et al. (1999) either in
brain tissue of normal, elderly individuals or in brain
tissue of individuals with neurodegenerative disease.
How can we reconcile this discrepancy? Although it is
possible that we did not detect infrequent mutations by
the use of automated mtDNA sequencing, the fPEA assay
effectively excludes the presence of significant levels of
the T414G mutation in the brain tissue samples. This
was the most frequent control-region mutation reported
by Michikawa et al. (1999); it was detected in fibroblast
cell lines from 8 of 14 individuals 165 years of age, and
it reached levels as high as 50%.
It is possible that we did not detect some mtDNA
mutations in brain tissue because they were so detri-
mental as to cause neuronal cell death. We think that
this explanation is unlikely, because, even at high per-
centage levels, the control-region mutations in the fi-
broblast cell lines had no discernible phenotypic effect
(Michikawa et al. 1999). Also, if the mutations (such as
the T414G transversion) were causing neuronal loss, one
would expect to detect the mutation in a whole-brain
homogenate, because some brain cells would contain
intermediate or low levels of mutant mtDNA.
Another possibility is that there may be phenotypical-
ly significant mtDNA mutations in the brain but that
these occur in segments of the control region that are
outside the span of our sequencing primers. This pos-
sibility also seems unlikely, because we have sequenced
the entire control region (nt 16074–16569 and 1–576)
in brain DNA from the 47 individuals with DLB (Chin-
nery et al. 2000). In a search for any of the eight poly-
morphisms that Michikawa et al. (1999) observed in
fibroblasts, we found one patient with DLB who was
homoplasmic for the T146C mutation and four individ-
uals with DLB who were homoplasmic for the T152C
mutation.We have seen both these base changes in blood
samples from young control subjects (T146C in 23% of
4,360 sequences from an ethnically diverse population
and in 10% of 1,961 sequences from awhite population;
T152C in 28% of 4,360 sequences from an ethnically
diverse population and in 19% of 1,961 sequences from
a white population), and, in the present study, it is most
likely that they are inherited polymorphisms in the in-
dividuals who had DLB.
Finally, it is possible that the frequent occurrence of
high percentages of mutant mtDNA that were seen by
Michikawa et al. (1999) arose because those authors
studied fibroblast cell lines in culture. Rapid changes in
the percentages of both pathogenic and neutral heter-
oplasmic mtDNA mutations have been seen in cultured
fibroblast cell lines, despite the fact that the level of het-
eroplasmy may remain relatively constant in vivo (e.g.,
see Bidooki et al. 1997). However, random drift can
explain the high frequency of the T414G mutation seen
by Michikawa et al. (1999) only if the mutations were
present, at moderately high levels, in most of the fibro-
blasts in vivo. It therefore seems most likely that there
is some form of selection bias—either in quiescent fi-
broblasts in vivo or in the fibroblast cultures—that fa-
vors the mtDNA molecules containing the novel control
region–sequence variants. The latter scenario is appeal-
ing because of the nonphysiological conditions that ac-
company fibroblast cell culture. However, on the basis
of the extensive analyses reported here, we conclude that
such selection does not act in brain neurons. In conclu-
sion, our findings in human brain tissue do not support
the hypothesis that somatic mtDNA control region mu-
tations contribute to the aging process in vivo.
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